Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Net Income: 2013-2025

Historic Net Income for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $9.0 million.

  • Coherus Oncology's Net Income fell 75.61% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 217.73%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • Per Coherus Oncology's latest filing, its Net Income stood at $9.0 million for Q3 2025, which was down 97.38% from $342.6 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Net Income peaked at $342.6 million during Q2 2025, and registered a low of -$172.9 million during Q1 2021.
  • For the 3-year period, Coherus Oncology's Net Income averaged around $50.2 million, with its median value being $9.0 million (2025).
  • Per our database at Business Quant, Coherus Oncology's Net Income plummeted by 586.19% in 2021 and then skyrocketed by 717.15% in 2025.
  • Over the past 5 years, Coherus Oncology's Net Income (Quarterly) stood at -$45.7 million in 2021, then declined by 28.75% to -$58.9 million in 2022, then crashed by 35.30% to -$79.7 million in 2023, then soared by 348.34% to $197.8 million in 2024, then slumped by 75.61% to $9.0 million in 2025.
  • Its last three reported values are $9.0 million in Q3 2025, $342.6 million for Q2 2025, and -$9.2 million during Q1 2025.